GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

The researchers found that significantly lower rates of opioid overdose and alcohol intoxication were reported in patients with GIP/GLP-1 RA prescriptions compared with those without such ...

The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0% for GLP-1 RA users and 10.7% for nonusers.

Mohammad Ali Sheffeh, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ablation, according to a large Veterans Affairs database. New initiators ...

Combination therapy with GLP-1 RA and thiazolidinedione significantly reduces all-cause mortality and cardiovascular mortality in type 2 diabetes patients. The study found an increased risk of ...

A nationwide study using the French National Health Data System (SNDS) (2013-2021) evaluated the short-term association between GLP-1 RA and suicidal behaviors. The SNDS contains anonymized ...

SGLT2i also significantly reduced the risk of heart failure hospitalization or cardiovascular death by 24% and 22% in patients receiving and not receiving GLP-1 RA, respectively. The investigators ...

The median time receiving treatment was 3.9 months. The researchers found that GLP-1 RA use was associated with a lower rate of any hyperkalemia and moderate-to-severe hyperkalemia compared with ...